In the past, according to the NCCN guidelines, cancer patients with a high risk or an intermediate risk of FN combined with ≥1 patient-specific risk factor were recommended to use a full dose of G-CSF to prevent FN during chemotherapy. The gene discussed is CSF3; the disease is cancer.